Potential immunological action of purine nucleoside analogues

Drugs
G Dighiero

Abstract

Purine nucleoside analogues are a new class of drugs with activity against nondividing lymphocytes; thus, they should play a major role in the treatment of low grade lymphoid malignancies. As these drugs are active against resting lymphocytes, harmful effects related to this action were expected and have been reported. However, the toxic effects on resting lymphocytes observed during treatment of lymphoid malignancies may potentially be of some benefit in patients with autoimmune diseases. To substantiate this possibility, a considerable amount of work needs to be carried out in order to better define the mechanism of action of these drugs, as well as their potential activity on different immunological effectors. Also, studies in animal models of autoimmune disease should be undertaken.

Citations

Jun 14, 2002·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Vincent GrégoirePierre Scalliet
Jul 9, 2003·Journal of Pediatric Hematology/oncology·Jenna D GoldbergGeorgia B Vogelsang
Sep 14, 2001·Clinical Oncology : a Journal of the Royal College of Radiologists·M Churn, V Clough
Nov 13, 2004·Experimental Hematology·Franck E NicoliniMauricette Michallet
Jun 21, 2005·Blood Reviews·Farhad Ravandi, Susan O'Brien

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.